Future research should improve the diagnostic criteria by incorporating insulin resistance (such as fasting insulin, HOMA-IR), abdominal adiposity measures, other related metabolic factors, and integrating medication history to enhance the precision of metabolic dysfunction assessment. This evidence concerns the gene INS and Insulin resistance.